Understanding how prostate cancer develops resistance to treatment at the single cell level
Official title: Studying the evolution of drug resistance in prostate cancer at the single cell level
Funded at Columbia University Health Sciences · NIH-11072772 · Data updated 2026-11-12
This study is looking at how prostate cancer cells change and become resistant to treatments, so we can find better ways to help patients like you respond to therapy and improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $164,500 |
| NIH project number | 3U54CA274506-02S1 |
| Project ID | NIH-11072772 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced prostate cancer who have not responded well to existing therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the mechanisms behind drug resistance in prostate cancer by examining individual cancer cells. It aims to identify how these cells adapt and evolve in response to treatments, which can lead to treatment failure and disease progression. By utilizing advanced technologies and computational methods, the study will create detailed molecular interaction networks that reveal how cancer cells communicate and interact with their environment. This approach seeks to uncover universal targets for more effective therapies in heterogeneous tumors.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for prostate cancer that overcome drug resistance.
How similar studies have gone: Previous research has shown promise in understanding drug resistance in cancer using similar methodologies, indicating potential for success in this approach.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Califano, Andrea — Columbia University Health Sciences
- Study coordinator: Califano, Andrea
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.